← Back

Kidswell Bio Corporation

Kidswell Bio Corporation develops pharmaceutical products for pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline includes GBS-001 and GBS-010 for oncology, GBS-007 for ophthalmic disease, and GBS-011 for renal disease. Additional candidates include GCT-103 for pediatric cerebral palsy, GCT-102 for congenital entero-neuropathy, SQ-104 for osteonecrosis of the femoral head, modified thymidine kinase for glioblastoma, and Gene X for spinal cord injury. Formerly Gene Techno Science Co.,Ltd., it changed its name to Kidswell Bio Corporation in July 2021, was incorporated in 2001, and is headquartered in Chuo, Japan.

Price · split & dividend adjusted
News & notes moving 4584.JP
JapanPhilippinesUnited States
Artificial Intelligence▲

Onex, Kidswell, Sanyo Trading, Wada Kosan and others among individual news announced on the 18th

Among the main individual items announced on the 18th, Onex will acquire land for an AI data center and power receiving facilities and launch a new business; Kidswell will sell listed securities it holds and record an extraordinary gain; and Sanyo Trading announced that misappropriation of funds was discovered at its U.S. subsidiary and that it will set up a special investigation committee. Wada Kosan revised up its earnings plan for the cumulative second quarter of the fiscal year ending February 2027, covering March through August, raising standalone operating profit to 2 billion yen from 1.6 billion yen, up 27.5 percent year on year, while leaving its full-year plan unchanged and increasing its dividend plan to 67 yen per year from 60 yen, against 72 yen in the previous fiscal year. Yamaichi Electronics resolved to build a fourth plant in the Philippines, with total investment of about 6.5 billion yen and operations scheduled to begin in the second half of fiscal 2028. SQUEEZE announced a capital and business alliance with Hulic, raising Hulic's ownership stake to 6.97 percent from 1.98 percent. Nippon Insulator revised up its consolidated operating profit for the cumulative second quarter of the fiscal year ending March 2027, covering April through September, to 384 million yen from 281 million yen, down 44.6 percent from a year earlier. Nikkato revised up its standalone operating profit for the fiscal year ending March 2027 to 1.22 billion yen from 1.1 billion yen, up 13.9 percent year on year. Shoei Yakuhin revised up its consolidated operating profit for the cumulative second quarter of the fiscal year ending March 2027 to 424 million yen from 208 million yen, up 76.7 percent year on year. Inter Action won a large order worth 747 million yen for image sensor inspection-related products, with revenue expected to be recorded between September 2026 and May 2027.
About megatrends
Artificial Intelligence › AI Data Center & Build-out ▲Capital
Cloud & Digital Infrastructure › Telecom Towers, Fiber & Colocation Capital
3176.JP · Regulation · Negative Misappropriation of funds was discovered at Sanyo Trading's U.S. subsidiary, prompting a special investigation committee.
5367.JP · Capital · Positive Nikkato revised up its standalone operating profit forecast for the fiscal year ending March 2027 to 1.22 billion yen from 1.1 billion yen.
7725.JP · Demand · Positive Inter Action won a large order worth 747 million yen for image sensor inspection.
4584.JP · Capital · Positive Kidswell will sell listed securities it holds and record an extraordinary gain.
558A.JP · Capital · Positive SQUEEZE announced a capital and business alliance with Hulic, raising Hulic's stake to 6.97% from 1.98%.
6941.JP · Capital · Positive Yamaichi Electronics resolved to build a fourth plant in the Philippines with about 6.5 billion yen investment, operations from H2 fiscal 2028.
Read original ↗
ウエルスアドバイザー·11dRead more →